Company intelligence / Profile preview

TidalSense

Cambridge, England, United Kingdomtidalsense.com ↗

Ownership: Private
Development stage: Commercial

Overview

TidalSense’s flagship product N-Tidal™ Diagnose has received EU MDR class IIa CE-mark regulatory clearance for point-of-care COPD diagnosis. Clinical studies have benchmarked the device on over 1,000 patients with more than two million breaths analyzed. The technology enables rapid (<5 min), accurate diagnosis without forced breathing maneuvers or specialist training. Real-world evidence generation programs are ongoing to expand indications.

Therapeutic areas: Pulmonology
Modalities: DeviceDigital biomarker platformAI-driven diagnostics and monitoring solutions
Industry: Physiological Monitoring

Drug pipeline

2 assets

N-Tidal Diagnose

Commercial

Indications: COPD

1 more asset in the full pipeline.

Request access →

Partnerships

Not explicitly listed in public sources as of June 2025.

Beyond the preview

Go deeper on TidalSense.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TidalSense.

Explore the full profile